PMID- 37494698
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20240324
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 142
IP  - 22
DP  - 2023 Nov 30
TI  - Impact of cytogenetic abnormalities on the risk of disease progression in 
      solitary bone plasmacytomas.
PG  - 1871-1878
LID - 10.1182/blood.2023021187 [doi]
AB  - Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma 
      (MM) after definitive radiation therapy as their primary treatment. Whether the 
      presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ 
      hybridization (FISH) in the clonal plasma cells, obtained either directly from 
      the diagnostic SBP tissue or the corresponding bone marrow examination at the 
      time of diagnosis, is associated with a shorter time to progression (TTP) to MM 
      is unknown. This study evaluated all patients diagnosed with SBP at the Mayo 
      Clinic from January 2012 to July 2022. The presence of del(17p), t(14;16), 
      t(4;14), or +1q (gain or amplification) by FISH in clonal plasma cells was 
      defined as HR. A total of 114 patients were included in this cohort, and baseline 
      FISH was available for 55 patients (48%), of which 22 were classified as HR 
      (40%). The median TTP to MM for patients with SBP and HR FISH was 8 months (95% 
      confidence interval [CI], 6.3-26) compared with 42 months (95% CI, 25-not reached 
      [NR]) in patients with SBP without HR FISH (P < .001). In a multivariate 
      analysis, only HR FISH was a significant predictor for shorter TTP to MM, 
      independent of minimal marrow involvement and an abnormal serum free light chain 
      ratio at diagnosis. Deletion (17p) and gain 1q abnormalities were the most common 
      FISH abnormalities responsible for the short TTP to MM. Thus, assessing for HR 
      FISH abnormalities in clonal plasma cells derived from either the diagnostic SBP 
      tissue or the staging bone marrow examination of patients with newly diagnosed 
      SBP is feasible and prognostic for a shorter TTP to MM.
CI  - (c) 2023 by The American Society of Hematology.
FAU - Yadav, Udit
AU  - Yadav U
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Kumar, Shaji K
AU  - Kumar SK
AUID- ORCID: 0000-0001-5392-9284
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Baughn, Linda B
AU  - Baughn LB
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, MN.
FAU - Dispenzieri, Angela
AU  - Dispenzieri A
AUID- ORCID: 0000-0001-8780-9512
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Greipp, Patricia
AU  - Greipp P
AUID- ORCID: 0000-0002-5536-9011
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, MN.
FAU - Ketterling, Rhett
AU  - Ketterling R
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, MN.
FAU - Jevremovic, Dragan
AU  - Jevremovic D
AD  - Division of Hematopathology, Department of Laboratory Medicine and Pathology, 
      Mayo Clinic, Rochester, MN.
FAU - Buadi, Francis K
AU  - Buadi FK
AUID- ORCID: 0000-0003-3214-0203
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Dingli, David
AU  - Dingli D
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Lacy, Martha Q
AU  - Lacy MQ
AUID- ORCID: 0000-0003-1193-1559
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Fonseca, Rafael
AU  - Fonseca R
AD  - Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ.
FAU - Bergsagel, P Leif
AU  - Bergsagel PL
AUID- ORCID: 0000-0003-1523-7388
AD  - Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ.
FAU - Ailawadhi, Sikander
AU  - Ailawadhi S
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
FAU - Roy, Vivek
AU  - Roy V
AUID- ORCID: 0000-0002-5950-4620
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
FAU - Parrondo, Ricardo
AU  - Parrondo R
AUID- ORCID: 0000-0002-9314-9933
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
FAU - Sher, Taimur
AU  - Sher T
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
FAU - Hayman, Suzanne R
AU  - Hayman SR
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Kapoor, Prashant
AU  - Kapoor P
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Leung, Nelson
AU  - Leung N
AUID- ORCID: 0000-0002-5651-1411
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
AD  - Division of Nephrology, Mayo Clinic, Rochester, MN.
FAU - Cook, Joselle
AU  - Cook J
AUID- ORCID: 0000-0001-5335-9533
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Binder, Moritz
AU  - Binder M
AUID- ORCID: 0000-0001-9014-9658
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Muchtar, Eli
AU  - Muchtar E
AUID- ORCID: 0000-0003-2210-2174
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Warsame, Rahma
AU  - Warsame R
AUID- ORCID: 0000-0003-0240-0326
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Kourelis, Taxiarchis V
AU  - Kourelis TV
AUID- ORCID: 0000-0001-8573-9434
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Go, Ronald S
AU  - Go RS
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Lin, Yi
AU  - Lin Y
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Seth, Abhishek
AU  - Seth A
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Lester, Scott C
AU  - Lester SC
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
FAU - Breen, William G
AU  - Breen WG
AD  - Department of Radiation Oncology, Mayo Clinic, Rochester, MN.
FAU - Kyle, Robert A
AU  - Kyle RA
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Gertz, Morie A
AU  - Gertz MA
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Rajkumar, S Vincent
AU  - Rajkumar SV
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
FAU - Gonsalves, Wilson I
AU  - Gonsalves WI
AD  - Division of Hematology, Mayo Clinic, Rochester, MN.
LA  - eng
GR  - P50 CA186781/CA/NCI NIH HHS/United States
GR  - R01 CA254961/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
CIN - Blood. 2023 Nov 30;142(22):1849-1850. PMID: 38032673
MH  - Humans
MH  - *Plasmacytoma/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Chromosome Aberrations
MH  - *Multiple Myeloma/diagnosis/genetics
MH  - Prognosis
MH  - Disease Progression
PMC - PMC10731916
COIS- Conflict-of-interest disclosure: R.F. reports consulting for AbbVie, Adaptive 
      Biotechnologies, AMGEN, AstraZeneca, Bayer, Binding Site, Bristol Myers Squibb 
      (Celgene), Millenium Takeda, Janssen, Juno, Kite, Merck, Pfizer, Pharmacyclics, 
      Regeneron, and Sanofi; is a member of scientific advisory boards for Adaptive 
      Biotechnologies, Caris Life Sciences, and ONCOtracker; is a member of board of 
      directors for Antengene (for profit) and AZBio (not for profit); and has a patent 
      for fluorescence in situ hybridization in multiple myeloma receiving  approximately $2000 per 
      year. The remaining authors declare no competing financial interests.
EDAT- 2023/07/26 19:11
MHDA- 2023/12/01 06:45
PMCR- 2024/11/30
CRDT- 2023/07/26 17:02
PHST- 2023/07/26 00:00 [accepted]
PHST- 2023/05/18 00:00 [received]
PHST- 2024/11/30 00:00 [pmc-release]
PHST- 2023/12/01 06:45 [medline]
PHST- 2023/07/26 19:11 [pubmed]
PHST- 2023/07/26 17:02 [entrez]
AID - S0006-4971(23)01770-6 [pii]
AID - 10.1182/blood.2023021187 [doi]
PST - ppublish
SO  - Blood. 2023 Nov 30;142(22):1871-1878. doi: 10.1182/blood.2023021187.